March news on Smooth Drug Development

Regardless COVID-19 situation, Smooth Drug Development has started several new projects in March:

• Smooth signed contract for data management and medical writing activities.
• We were awarded with a full service clinical trial of phase III in Buserelinum in Russia.
• Smooth was awarded with a project in pharmacoeconomics.
• Our company signed a contract with a leasdng Russian company for medical writing in COVID-19 disease.
• We were awarded with a phase IV project in TB.
• We were awarded with 4 data management projects.
• Our company is awarded with a bioequivalence trial with a combination of Indapamide + Telmisartan.
• We were awarded by a data management and medical writing project in orphan disease.

The company did not seize its activities amid the difficult epidemiology situation in Russia.

• CSR for a bioequivalence trial with Etoricoxibe is being finalized. 
• Most subjects in PID trial completed their treatment.
• Bromhexine CSR was submitted to Sponsor.
• All 5 sites in Sertaconazole trial were closed.
• All Ingalypt trial data was monitored by our Clinical Operations team. The data base was closed.
• Data in Enalapril 10, Enalapril 20 and Nimesulide was monitored by our Clinical Operations team.
• Enrollment in our schizophrenia trial was completed. We enrolled 90 patients in Russian sites.